Virtual Library
Start Your Search
A. Mezini
Author of
-
+
P1.04 - Poster Session with Presenters Present (ID 456)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Pulmonology
- Presentations: 2
- Moderators:
- Coordinates: 12/05/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P1.04-006 - Second Primary Lung Cancer: Five Years of a Single Center Experience in Its Diagnosis and Treatment (ID 4626)
14:30 - 14:30 | Author(s): A. Mezini
- Abstract
Background:
Second primary lung cancer (SPLC) constitute an important dimension of the burden of cancer survivorship that needs to be taken into account when defining strategies for surveillance, prevention and counseling. In last three decades the incidence of SPLC in patients that had a history of a prior cancer out of the respiratory system is estimated 2-8%. Relative risks of SPLC may be smaller than previously reported may benefit from increased surveillance. The goal of this study was to give an overview of SPLC regarding patients’ primary malignancy, their stage of lung cancer presentation and bringing to the light some possible risk factors. Such data will be helpful in calculation of the risk for SPLC as well as handling of risky patients for a better survival.
Methods:
This is a retrospective study for a period of 5 years where all the data that was gathered from clinical cartels of patients with lung cancer were analyzed using Pearson Chi-Square.
Results:
SPLC represents 2% of all lung cancers diagnosed during the period of study. The prior diagnose of cancer for this patients was breast cancer in 46% of cases, cervix cancer in 40% of cases and the other diagnosis 14% of cases. All the patients have been under oncologic treatment with radio or chemotherapy. 20% of these patients have been smokers prior to first malignancy. The average age of the patients with SPLC was 55 years old. The ratio male to female was 1:10. The most frequent hystotipe found was adenocarcinoma in 60% of cases meanwhile in all cases with a prior squamous cell cancer of cervix was found squamous cell carcinoma as SPLC. The average period of time from the prime cancer to the SPLC was 3.7 years. 73% of cases with SPLC underwent an anatomical resection of the tumor.
Conclusion:
This study shows that patients with the higher risk for a SPLC are premenopausal women with breast cancer and cervical cancer. Changes in the prevalence of risk factors and diagnostic techniques may have affected more recent risks. The relative risk of developing SPLC in smokers is unclear. SPLC after oncologic treatment is an issue that raises many questions.
-
+
P1.04-020 - Management of Lung Cancer in Patients with past Pulmonary Tuberculosis and Their Possible Causative Link (ID 4170)
14:30 - 14:30 | Author(s): A. Mezini
- Abstract
Background:
Lung cancer and tuberculosis cause significant morbidity and mortality worldwide. In the past, it was well known that lung cancer is a specific epidemiological successor of pulmonary tuberculosis (PTB) and that it often develops in scars caused by PTB. In recent years, the relevance of the two diseases has drawn attention in terms of the close epidemiological connection and chronic inflammation-associated carcinogenesis. Although studies have found a relationship between PTB and lung cancer, results for the long-term risk and the role of confounding factors remain inconclusive. Therefore, it is important to delineate the relationship between PTB and lung cancer.
Methods:
Clinical files of all patients diagnosed with lung malignancy between 2011 and 2016 were investigated retrospectively in terms of patient characteristics, definite histopathological diagnosis and stage of tumor, operation methods, and associated complications.
Results:
Mean age was 56.4 years. Past PTB was detected in 3% of operated carcinoma patients and in 6% of all patients diagnosed with lung malignancy. Central lung cancer was diagnosed in 80% of cases and peripheral in 20%. Epidermoid cancer was diagnosed in 51% of cases, adenocarcinoma in 24% and adenoepidermoid carcinoma in 25%. All cases of operable lung cancers were in stage I and II, while inoperable lung cancers were in stage IIIB and IV. Lobectomy was performed in 100% of the operated cases. None of the patients received anti-TB treatment preoperatively or postoperatively because by the time they were diagnosed with lung cancer, their sputum culture for M.Tuberculosis had converted negative. No postoperative mortality or reactivation of TB was seen.
Conclusion:
PTB is an important risk factor for lung cancer, possibly related to chronic inflammation and shared risk factors. Our study adds to the evidence that implicates chronic inflammation and pulmonary scarring in the etiology of lung cancer. However, further studies are needed to clarify whether there is a direct causative link between PTB and lung cancer. Surgery is the method of choice in treatment of lung cancer in subjects with past PTB history.
